As an example supporting the use of our methodology that combines cancer genomic analysis and genetic screening data analysis, the CRISPR knockout of the known TP53 negative regulator MDM2 decreases cell line fitness, in a manner anticorrelated to a TP53 knockout across cell lines. The gene discussed is TP53; the disease is cancer.